Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-1.971; its P/E ratio is -30.78; Crispr Therapeutics AG is scheduled to report earnings on April 30, 2024, and the estimated EPS forecast is $-1.45. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 201.21M	-	$ 70.00M	$ 100.00M	$ 6.00K
Gross Profit	$ 201.21M	-	$ 70.00M	$ 100.00M	$ -6.82M
EBIT	$ 89.58M	$ -111.74M	$ -76.82M	$ -51.74M	$ -131.54M
EBITDA	$ 94.48M	$ -106.81M	$ -71.86M	$ -46.69M	$ -125.69M
Net Income Common Stockholders	$ -131.15M	$ -65.31M	$ -77.74M	$ -53.06M	$ -110.58M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 1.69B	$ 1.74B	$ 1.77B	$ 1.88B	$ 1.82B
Total Assets	$ 2.23B	$ 2.09B	$ 2.20B	$ 2.24B	$ 2.24B
Total Debt	$ 238.63M	$ 241.59M	$ 245.18M	$ 240.27M	$ 244.02M
Net Debt	$ -1.46B	$ -1.50B	$ -1.52B	$ -1.64B	$ -1.57B
Total Liabilities	$ 346.77M	$ 359.04M	$ 380.99M	$ 389.47M	$ 367.58M
Stockholders Equity	$ 1.88B	$ 1.73B	$ 1.82B	$ 1.85B	$ 1.88B
Cash Flow	-
Free Cash Flow	$ -96.81M	$ -41.97M	$ -136.80M	$ 5.74M	$ -119.52M
Operating Cash Flow	$ -96.07M	$ -39.86M	$ -133.25M	$ 8.80M	$ -113.33M
Investing Cash Flow	$ -81.45M	$ 121.35M	$ 216.92M	$ 117.83M	$ -175.53M
Financing Cash Flow	$ 38.94M	$ 1.56M	$ 16.77M	$ 5.40M	$ 2.48M

Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Income Statement >

Crispr Therapeutics AG Debt to Assets

Balance Sheet >

Crispr Therapeutics AG Cash Flow

Cash Flow >

Crispr Therapeutics AG Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing